. 2020 Nov 4;21:100279. doi: 10.1016/j.aohep.2020.10.007

Table 1.

Characteristics of eligible studies.

First author	Year	Country	Groups	cases	Age	Sex (male, %)	Liver biochemical parameters	NOS scores
An W [19]	2020	China	Survivors	99	54.6 ± 15.6	38 (38.4)	AST^a, ALT^a, GGT^a, LDH^a	8
			Non-survivors	11	72.4 ± 7.1	6 (54.5)
Chen R [23]	2020	China	Survivors	1570	47.65 ± 69	865 (55.1)	AST^b, ALT^b, TBIL^b, LDH^b	7
			Non-survivors	50	68.65 ± 26.72	39 (78.0)
Chen T [25]	2020	China	Survivors	161	51.35 ± 21.69	88 (54.7)	AST, ALT, TBIL^a, ALB, LDH, GGT^a, ALP^a	7
			Non-survivors	113	68.06 ± 11.26	83 (73.5)
Chen TL [24]	2020	China	Survivors	36	72	18 (50.0)	AST, ALT, ALB, LDH, GLB	7
			Non-survivors	19	77	16 (84.2)
Deng Y [26]	2020	China	Survivors	116	43.52 ± 18.02	51 (44.0)	AST^a, ALT^a	7
			Non-survivors	109	68.3 ± 9.02	73 (67.0)
Du R [27]	2020	China	Survivors	158	56 ± 13.5	87 (55.1)	AST^a, ALT^a, TBIL^a, ALB^a, GGT^a, DBIL^a	8
			Non-survivors	21	70.2 ± 7.7	10 (47.6)
He X [28]	2020	China	Survivors	28	64.64 ± 12.34	18 (64.3)	ALT^b	9
			Non-survivors	26	69.64 ± 10.98	16 (61.5)
Li D [29]	2020	China	Survivors	136	54.76 ± 14.77	72 (52.9)	ALB^a, LDH^a	8
			Non-survivors	27	69.15 ± 13.12	14 (51.9)
Li Y [30]	2020	China	Survivors	20	<51	8 (40.0)	LDH^b	7
			Non-survivors	5	>51	4 (80.0)
Martín-Moro [43]	2020	Spain	Survivors	23	65.98 ± 45.83	14 (60.9)	LDH^a	9
			Non-survivors	11	76.01 ± 34.78	5 (45.5)
Ruan Q [31]	2020	China	Survivors	82	58.81 ± 27.92	53 (64.6)	AST^a, ALT^a, TBIL^a, ALB^a, LDH^a	8
			Non-survivors	68	66.29 ± 22.72	49 (72.1)
Wang D [32]	2020	China	Survivors	88	46.19 ± 17.94	41 (46.6)	AST^a, ALT^a, TBIL^a, LDH^a	7
			Non-survivors	19	72.64 ± 13.62	16 (84.2)
Wang Ke [33]	2020	China	Survivors	470	56.95 ± 15.62	224 (47.7)	AST^b, ALT^b, TBIL^b, ALB^b, LDH^b, GLB^b, DBIL^b	7
			Non-survivors	78	69.04 ± 12.24	55 (70.5)
Wang Kun [34]	2020	China	Survivors	277	46 ± 14.4	129 (46.6)	AST^a, ALT^a, TBIL^a, ALB^a, LDH^a, GLB^a, A/G^a	8
			Non-survivors	19	65.6 ± 12.6	11 (57.9)
Wang L [20]	2020	China	Survivors	274	68.7 ± 7.45	127 (46.4)	AST^a, ALT^a, LDH^a	7
			Non-survivors	65	76.35 ± 9.86	39 (60.0)
Wang Y [44]	2020	China	Survivors	211	57.7 ± 16.42	105 (49.8)	AST^a, ALT^a, TBIL^a, ALB^a, LDH^a	7
			Non-survivors	133	69.65 ± 11.24	74 (55.6)
Webb G [35]	2020	USA	Survivors	30	57.29 ± 10.9	20 (66.7)	TBIL^a, ALB^a	9
			Non-survivors	9	63.74 ± 5.25	5 (55.6)
Wu C [36]	2020	China	Survivors	157	47.73 ± 11.09	99 (63.1)	AST^a, ALT^a, TBIL^a, ALB^a, LDH^a, GLB^a,P-ALB^a, TP^a	7
			Non-survivors	44	67.54 ± 12.03	29 (65.9)
Xu B [37]	2020	China	Survivors	117	54.95 ± 17.26	59 (50.4)	AST^a, ALT^a	8
			Non-survivors	28	72.73 ± 7.23	17 (60.7)
Yang X [38]	2020	China	Survivors	20	51.9 ± 12.9	14 (70.0)	TBIL^a	8
			Non-survivors	32	64.6 ± 11.2	21 (65.6)
Yao Q [39]	2020	China	Survivors	96	47.87 ± 16.28	36 (37.5)	ALT, TBIL, ALB^a	8
			Non-survivors	12	62.99 ± 18.87	7 (58.3)
Zhang JG [42]	2020	China	Survivors	12	63.85 ± 15.9	–	LDH^b	8
			Non-survivors	18	62.47 ± 16.47	–
Zhang JP [40]	2020	China	Survivors	11	65.81 ± 15.38	6 (54.5)	ALB^a	8
			Non-survivors	8	77.69 ± 8.72	5 (62.5)
Zhang JX [41]	2020	China	Survivors	638	56.58 ± 18.57	306 (48.0)	AST^b, ALT^b, ALB^b, LDH^b	7
			Non-survivors	25	68.82 ± 13.36	15 (60.0)
Zhou F [14]	2020	China	Survivors	137	51.65 ± 9.74	81 (59.1)	ALT, ALB^a, LDH	8
			Non-survivors	54	69.35 ± 9.9	38 (70.4)

NOS, Newcastle–Ottawa Scale; AST, aspartate aminotransferase; ALT, alanine transaminase; TBIL, total bilirubin; ALB, albumin; LDH, lactic dehydrogenase; GLB, globulin; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; DBIL, direct bilirubin; A/G, ALB-to-GLB ratio; P-ALB, prealbumin.

This parameter was available as a continuous outcome in the study.

This parameter was available as a dichotomous outcome in the study.

No superscript means this parameter was available as both continuous and dichotomous outcomes in the study.